Catalyst calendar
Data as of 2026-08-19 16:00 UTC · tracked universe polled every 15 minutes
Three kinds of date: a PDUFA date (the deadline the FDA sets itself to decide on a drug application), an AdCom (an FDA advisory-committee meeting that reviews it in public), and a readout window (when a trial's results are expected). Dates marked confirmed by the company come from an 8-K or press-release quote; our estimate is a rule-derived window off the trial's registered primary-completion date (see methodology) — never shown the same way. Today: 200 estimated readout windows and 0 disclosed PDUFA/AdCom dates.
Next 7 days
| Date | Ticker | Phase | Event |
|---|---|---|---|
| 2026-10-31 in 10w | $AMGN | Phase 1 | A Study Evaluating Anvumetostat in Combination With Other Therapies in… NCT06360354 |
| 2026-10-31 in 10w | $AMGN | Phase 1 | Anvumetostat Alone or in Combination With Other Therapies in Subjects With… NCT06333951 |
| 2026-10-31 in 10w | $BMY | Phase 1 | A Rollover Study of CC-122 NCT05688475 |
| 2026-11-13 in 12w | $REGN | Phase 1 | A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination… NCT04626635 |
| 2026-11-15 in 13w | $AMGN | Phase 1 | A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin… NCT07160257 |
| 2026-11-17 in 13w | $BMY | Phase 1 | A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986521 in… NCT07283263 |
| 2026-11-18 in 13w | $AMGN | Phase 1 | Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and… NCT07523711 |
| 2026-11-19 in 13w | $VRTX | Phase 1 | Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in… NCT07283770 |
| 2026-11-30 in 15w | $AMGN | Phase 1 | A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors… NCT05094336 |
| 2026-12-04 in 15w | $PFE | Phase 1 | A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant… NCT07231991 |
| 2026-12-04 in 15w | $REGN | Phase 1 | A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe… NCT06452771 |
| 2026-12-09 in 16w | $INCY | Phase 1 | Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent… NCT07049575 |
| 2026-12-17 in 17w | $AMGN | Phase 1 | Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C… NCT04185883 |
| 2026-12-29 in 19w | $ALNY | Phase 1 | A Study to Evaluate ALN-4285 in Adult Healthy Volunteers NCT07295717 |
| 2026-12-31 in 19w | $SRPT | Phase 1 | Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy NCT06138743 |
| 2026-12-31 in 19w | $AMGN | Phase 1 | Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab… NCT03319940 |
| 2026-12-31 in 19w | $ARGX | Phase 1 | A Study to Assess the Safety of ARGX-124 in Healthy Volunteers NCT07377396 |
| 2027-01-01 in 19w | $INCY | Phase 1 | A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic… NCT06179160 |
| 2027-01-04 in 20w | $INCY | Phase 1 | A Study to Assess the Safety and Pharmacokinetics of INCB123667 When… NCT07559396 |
| 2027-01-06 in 20w | $INCY | Phase 1 | A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent… NCT06843408 |
| 2027-01-06 in 20w | $REGN | Phase 1 | A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With… NCT05259709 |
| 2027-02-02 in 24w | $BIIB | Phase 1 | A Study to Learn More About the Safety of BIIB145 and How it is Processed in… NCT07225517 |
| 2027-02-02 in 24w | $VRTX | Phase 1 | A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1… NCT06185764 |
| 2027-02-22 in 27w | $REGN | Phase 1 | Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity NCT07594093 |
| 2027-02-26 in 27w | $VRTX | Phase 1 | Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy… NCT07378865 |